07:19 AM EDT, 03/26/2024 (MT Newswires) -- Gyre Therapeutics ( GYRE ) said Tuesday it swung to a fiscal 2023 net loss of $1.41 per diluted share from net income of $0.03 a year earlier.
Analyst estimates were not available for comparison.
Revenue for the year ended Dec. 31 was $113.5 million, up from $102.3 million a year earlier.